Trillium Therapeutics is developing innovative immune-oncology drug candidates designed to improve the lives of cancer patients. Our lead program, TTI-621, is a SIRPαFc fusion protein designed to block the CD47 "do not eat" signal and activate both the innate and adaptive immune systems. Below please find a list of our current clinical trials.

TTI-621-01 (NCT02663518) is a multicenter, open-label phase 1a/b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and select solid tumors.

TTI-621-02 (NCT02890368) is a multicenter, open-label phase 1 trial that is testing intratumoral injections of TTI-621 in subjects with relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides (a form of cutaneous T cell lymphoma).

 TTI-621 has recently been granted an Orphan Drug Designation by the FDA for the treatment of cutaneous T-cell lymphoma.


Trillium Therapeutics Inc.’s Compassionate Use Policy can be found here.


Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.